| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Diaxonhit (EPA: ALEHT)
ALEHT Technical Analysis
5
| As on 1st Nov 2017 ALEHT Share Price closed @ 5.13 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 1.13 & Strong Buy for SHORT-TERM with Stoploss of 3.87 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ALEHT Share Price
| Open | 5.10 | Change | Price | % |
| High | 5.15 | 1 Day | 0.03 | 0.59 |
| Low | 5.00 | 1 Week | 0.00 | 0.00 |
| Close | 5.13 | 1 Month | -0.27 | -5.00 |
| Volume | 22213 | 1 Year | 4.82 | 1554.84 |
| 52 Week High 6.00 | 52 Week Low 0.22 | ||||
EPA France Most Active Stocks
| MT | 4.53 | 12.97% |
| MT | 4.53 | 12.97% |
| GSZ | 17.56 | 3.97% |
| BRS | 12.00 | 0.00% |
| VK | 4.72 | 0.43% |
| ALALO | 0.04 | 0.00% |
| CS | 26.31 | 1.47% |
| TEC | 67.40 | 0.40% |
| ACA | 14.98 | 0.00% |
| ALAUP | 0.20 | -13.04% |
EPA France Top Gainers Stocks
EPA France Top Losers Stocks
| ALEHT Daily Charts |
ALEHT Intraday Charts |
Whats New @ Bazaartrend |
ALEHT Free Analysis |
|
|
ALEHT Important Levels Intraday
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| RESISTANCE | 5.27 |
| RESISTANCE | 5.21 |
| SUPPORT | 5.05 |
| SUPPORT | 4.99 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
ALEHT Target for Month January
| 4th UP TARGET | 7.1 |
| 3rd UP TARGET | 6.46 |
| 2nd UP TARGET | 6.06 |
| 1st UP TARGET | 5.67 |
| 1st DOWN TARGET | 4.53 |
| 2nd DOWN TARGET | 4.14 |
| 3rd DOWN TARGET | 3.74 |
| 4th DOWN TARGET | 3.1 |
ALEHT Weekly Target
| 4th UP TARGET | 0.00 |
| 3rd UP TARGET | 0.00 |
| 2nd UP TARGET | 0.00 |
| 1st UP TARGET | 0.00 |
| 1st DOWN TARGET | 0.00 |
| 2nd DOWN TARGET | 0.00 |
| 3rd DOWN TARGET | 0.00 |
| 4th DOWN TARGET | 0.00 |
ALEHT Target for Year 2021
| 4th UP TARGET | 0 |
| 3rd UP TARGET | 0 |
| 2nd UP TARGET | 0 |
| 1st UP TARGET | 0 |
| 1st DOWN TARGET | 0 |
| 2nd DOWN TARGET | 0 |
| 3rd DOWN TARGET | 0 |
| 4th DOWN TARGET | 0 |
Diaxonhit ( EPA France Symbol : ALEHT )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ALEHT Business Profile
Diaxonhit is engaged in the discovery and commercialization of in-vitro diagnostic products in transplantation, infectious diseases, and cancer diagnosis specialty areas. It markets a proprietary test, Tetanus Quick Stick, used in emergency clinics for the evaluation of the protective status of a patient against tetanus. The company's in-house development products include the BJI InoPlex kit, a test that allows the detection of infections linked to articular prosthesis; and EHT Dx15, a test for the diagnosis of thyroid cancer, as well as licensed product comprises AlloMap, a gene-expression profiling based blood test for regular and non-invasive surveillance of heart transplant recipients for acute cellular rejection. It is also developing companion diagnostics for resistant and breast cancers; and tests to monitor the direct effect of drug activity. The company was formerly known as Exonhit S.A. and changed its name to Diaxonhit in December 2012. Diaxonhit was founded in 1997 and is headquartered in Paris, France.
© 2005-2019 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
